Previous 10 | Next 10 |
Mechelen, Belgium ; 4 June 2021 ; 07 . 01 CET ; – Galapagos NV (Euronext & Nasdaq: GLPG) today announced that primary and secondary endpoint results from the phase 3 SELECTION induction and maintenance study (NCT029145...
Mechelen, Belgium, 27 May 2021, 22 :01 CET, – Galapagos NV (Euronex t & Nasdaq: GLPG) today announced that 15 abstracts , including scientific updates, and data providing further understanding on the profile of filgotinib as a tre...
Galapagos (GLPG) announces that the first patient has been enrolled in its study to evaluate the effectiveness and safety of filgotinib in treating patients with rheumatoid arthritis ((RA)) in a real-world setting.The FILOSOPHY study is a prospective, non-interventional cohort study enrolling...
Study uses mobile device technology to support capture of patient - reported outcomes during early and ongoing use of stud y treatment amongst patients with rheumatoid arthritis Mechelen , Belgium ; 18 May 2021 ; 22.0...
Soligenix (SNGX) -22% as company now plans to submit the NDA in the 1H22.LM Funding America (LMFA) -11%.Senmiao Technology (AIHS) -7%.InnSuites Hospitality (IHT) -5%.Ra Medical Systems (RMED) -6%.Galapagos (GLPG) -5%.Stealth BioTherapeutics (MITO) -5%.Luokung Technology (LKCO) -5%. For...
Galapagos NV (GLPG) Q1 2021 Earnings Conference Call May 07, 2021 08:00 AM ET Company Participants Elizabeth Goodwin - VP of IR Onno Van De Stolpe - Co-Founder & CEO Bart Filius - President & COO Walid Abi-Saab - Chief Medical Officer Piet Wigerinck - Chief Scientific Officer Michele ...
Image source: The Motley Fool. Galapagos NV (NASDAQ: GLPG) Q1 2021 Earnings Call May 7, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Galapagos NV (GLPG) Q1 2021 Earnings Call Transcript
First three months 202 1 financial results : Group revenues and other income of € 124 . 2 million Operating loss of € 5 0.8 million Net profit of € 9 .4 m...
Mechelen, Belgium ; 30 April 2021 , 22.01 CET; regulated information – – Galapagos NV (Euronext & NASDAQ : GLPG) announced today that its supervisory b oard created 2, 7 36,250 subscripti...
Galapagos' (GLPG) collaboration partner Gilead Sciences (GILD) has submitted an application to Japan’s Pharmaceuticals and Medical Devices Agency ((PMDA)) for approval of filgotinib for an additional indication to treat moderately to severely active ulcerative colitis ((UC)). This late...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...